ZBIO
ZENAS BIOPHARMA (ZBIO)
NASDAQ
$20.21-$0.60 (-2.86%)
Price as of Jun 23, 2026 4:10 PM EDT
  • $1.3B
    Market Cap
  • 119.64%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
Income Statement
Total Operating Revenue
10.0M
+100.00%
5.0M
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
Gross Profit
10.0M
+100.00%
5.0M
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
Research and Development Expense
-168.1M
+20.79%
-139.1M
N/A
Depreciation and Amortization Expense
56,000
-59.12%
137,000
N/A
Total Operating Expenses
393.1M
+132.73%
168.9M
N/A
Operating Profit
-383.1M
+133.73%
-163.9M
N/A
Interest Income
12.2M
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
12.2M
N/A
0
N/A
Total Nonoperating Income and Expense
5.2M
-28.49%
7.3M
N/A
Income before Taxes
-377.8M
+141.32%
-156.6M
N/A
Income Taxes
-79,000
-118.41%
429,000
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
Net Income
-377.7M
+140.62%
-157.0M
N/A
Net Income from Continuing Operations Applicable to Common
-377.8M
+141.32%
-156.6M
N/A
Basic EPS and Net Income
-8.44
-29.02%
-11.89
N/A
Diluted EPS and Net Income
-8.44
-29.02%
-11.89
N/A
Basic Weighted Average Shares
44.7M
+238.89%
13.2M
N/A
Diluted Weighted Average Shares
44.7M
+238.89%
13.2M
N/A
Balance Sheet
Cash and Cash Equivalents
110.6M
-65.40%
319.7M
N/A
Short-Term Investments
232.6M
+649.58%
31.0M
N/A
Cash and Cash Equivalents and Short-Term Investments
343.2M
-2.16%
350.8M
N/A
Total Current Assets
351.2M
-1.34%
355.9M
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
34,000
-81.62%
185,000
N/A
Total Long-Term Assets
13.8M
+7.41%
12.9M
N/A
Total Assets
383.6M
+3.70%
370.0M
N/A
Income Taxes Payable
118,000
-44.08%
211,000
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
Total Current Liabilities
62.6M
+9.35%
57.3M
N/A
Total Long-Term Debt
78.6M
+287.37%
20.3M
N/A
Total Long-Term Liabilities
78.8M
+36,068.35%
218,000
N/A
Total Liabilities
141.5M
+146.04%
57.5M
N/A
Retained Earnings
-765.1M
+97.51%
-387.4M
N/A
Total Stockholders Equity
242.1M
-22.50%
312.5M
N/A
Total Shares Outstanding
54.5M
+30.37%
41.8M
N/A
Cash Flow
Cash from Operating Activities
-172.3M
+44.00%
-119.7M
N/A
Capital Expenditures
18,000
-86.26%
131,000
N/A
Cash from Investing Activities
-251.9M
+724.45%
-30.6M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
Cash from Financing Activities
215.3M
-47.87%
413.0M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
Operating Margin
-3,830.57%
N/A
N/A
N/A
Return on Assets
-100.25%
N/A
N/A
N/A
Return on Equity
-136.22%
N/A
N/A
N/A
Revenue Growth
100.00%
N/A
N/A
N/A
Current Ratio
5.61
N/A
N/A
N/A
Cash Ratio
1.77
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow